TG Therapeutics Inc. (TGTX) Earns “Buy” Rating from FBR & Co
Other research analysts also recently issued reports about the company. S&P Equity Research reduced their target price on TG Therapeutics from $7.15 to $6.40 in a research note on Wednesday, August 24th. Brean Capital reiterated a buy rating on shares of TG Therapeutics in a research note on Monday, June 13th. Roth Capital reiterated a buy rating and set a $33.00 target price on shares of TG Therapeutics in a research note on Thursday, June 9th. SunTrust Banks Inc. initiated coverage on TG Therapeutics in a research note on Friday, May 27th. They set a buy rating and a $18.00 target price for the company. Finally, Zacks Investment Research downgraded TG Therapeutics from a strong-buy rating to a hold rating in a research note on Thursday, July 14th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $20.81.
TG Therapeutics (NASDAQ:TGTX) opened at 7.72 on Monday. TG Therapeutics has a 1-year low of $5.41 and a 1-year high of $14.87. The firm’s 50-day moving average price is $6.44 and its 200 day moving average price is $7.43. The firm’s market capitalization is $420.40 million.
TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by $0.04. TG Therapeutics had a negative return on equity of 58.77% and a negative net margin of 40,142.11%. On average, analysts predict that TG Therapeutics will post ($1.22) EPS for the current year.
A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Group LTD increased its stake in TG Therapeutics by 152.8% in the first quarter. BlackRock Group LTD now owns 17,443 shares of the biopharmaceutical company’s stock valued at $149,000 after buying an additional 10,542 shares during the period. BlackRock Advisors LLC boosted its position in shares of TG Therapeutics by 14.5% in the second quarter. BlackRock Advisors LLC now owns 18,131 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 2,296 shares in the last quarter. Mariner Wealth Advisors LLC boosted its position in shares of TG Therapeutics by 1.4% in the first quarter. Mariner Wealth Advisors LLC now owns 18,286 shares of the biopharmaceutical company’s stock valued at $156,000 after buying an additional 255 shares in the last quarter. SECOR Capital Advisors LP bought a new position in shares of TG Therapeutics during the second quarter valued at $187,000. Finally, Emerald Acquisition Ltd. bought a new position in shares of TG Therapeutics during the second quarter valued at $190,000. Institutional investors and hedge funds own 54.66% of the company’s stock.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.